Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Files An 8-K Other Events

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Files An 8-K Other Events
Item 8.01.Other Events.

Story continues below

On December29, 2017, Atara Biotherapeutics, Inc. issued a press release titled “Atara Biotherapeutics Announces FDA Clearance to Initiate Two Phase3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD),” a copy of which is attached hereto as Exhibit99.1 and is incorporated by reference herein.

Item 8.01.Financial Statements and Exhibits.

(d)Exhibits

Exhibit

Number

Description

99.1 Press Release, dated December 29, 2017.


Atara Biotherapeutics, Inc. Exhibit
EX-99.1 2 d489039dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atara Biotherapeutics Announces FDA Clearance to Initiate Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein- Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) – Pivotal studies to commence imminently – – Primary endpoint results and EU conditional marketing authorization submission expected in the first half of 2019 – – Company to host conference call and webcast today at 8:00 a.m. EST – SOUTH SAN FRANCISCO,…
To view the full exhibit click here

About Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, a humanized antibody targeting myostatin.

An ad to help with our costs